Objective. Immune complex (IC) deposition activates polymorphonuclear neutrophils (PMNs), increases vascular permeability, and leads to organ damage in systemic lupus erythematosus and rheumatoid arthritis. The bioactive lipid sphingosine 1-phosphate (S1P), acting via S1P receptor 1 (S1P 1 ), is a key regulator of endothelial cell (EC) barrier function. This study was undertaken to investigate whether augmenting EC integrity via S1P 1 signaling attenuates inflammatory injury mediated by ICs.
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Objective. Immune complex (IC) deposition activates polymorphonuclear neutrophils (PMNs), increases vascular permeability, and leads to organ damage in systemic lupus erythematosus and rheumatoid arthritis. The bioactive lipid sphingosine 1-phosphate (S1P), acting via S1P receptor 1 (S1P 1 ), is a key regulator of endothelial cell (EC) barrier function. This study was undertaken to investigate whether augmenting EC integrity via S1P 1 signaling attenuates inflammatory injury mediated by ICs.
Methods. In vitro barrier function was assessed in human umbilical vein endothelial cells (HUVECs) by electrical cell-substrate impedance sensing. Phosphorylation of myosin light chain 2 (p-MLC-2) and VE-cadherin staining in HUVECs were assessed by immunofluorescence. A reverse Arthus reaction (RAR) was induced in the skin and lungs of mice with S1P 1 deleted from ECs (S1P 1 EC-knockout [ECKO] mice) and mice treated with S1P 1 agonists and antagonists.
Results. S1P 1 agonists prevented loss of barrier function in HUVECs treated with IC-activated PMNs. S1P 1 ECKO and wild-type (WT) mice treated with S1P 1 antagonists had amplified RAR, whereas specific S1P 1 agonists attenuated skin and lung RAR in WT mice. ApoM-Fc, a novel S1P chaperone, mitigated EC cell barrier dysfunction induced by activated PMNs in vitro and attenuated lung RAR. Expression levels of p-MLC-2 and disruption of VE-cadherin, each representing manifestations of cell contraction and destabilization of adherens junctions, respectively, that were induced by activated PMNs, were markedly reduced by treatment with S1P 1 agonists and ApoM-Fc.
Conclusion. Our findings indicate that S1P 1 signaling in ECs modulates vascular responses to IC deposition. S1P 1 agonists and ApoM-Fc enhance the EC barrier, limit leukocyte escape from capillaries, and provide protection against inflammatory injury. The S1P/S1P 1 axis is a newly identified target to attenuate tissue responses to IC deposition and mitigate end-organ damage.
Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), though complex and heterogeneous, share the basic pathophysiologic mechanisms of immune complex (IC) deposition in tissues and neutrophil activation that cause end-organ damage. Circulating ICs induce neutrophil activation by both Fc and complement receptors which trigger the release of proinflammatory chemokines and cytokines that lead to endothelial cell (EC) barrier dysfunction and increase vascular permeability (1, 2) . Loss of EC barrier integrity has been implicated in inflammatory injury in mouse models of RA (3) and SLE (4) . When the EC integrity is compromised, plasma proteins extravasate and neutrophils transmigrate via paracellular (interendothelial) routes orchestrated by activated adhesion molecules (5) . Paracellular transmigration is mediated in part by phosphorylation of VE-cadherin and transient separation of adherens junctions, which creates intercellular gaps (6, 7) . Enhancing barrier integrity with pharmacologic or genetic approaches has been shown to impede both vascular leakage and neutrophil transmigration in animals treated with lipopolysaccharide (LPS) or histamine, respectively, to induce vascular permeability (8, 9) . We hypothesized that augmenting EC barrier function would attenuate inflammatory injury mediated by ICs. This approach has the potential to limit IC deposition and leukocyte transmigration into tissues, yet EC integrity has not been pharmacologically targeted in either SLE or RA.
Sphingosine 1-phosphate (S1P), a bioactive lipid secreted mainly by red blood cells (RBCs), ECs, and activated platelets, is a key regulator of EC barrier function and lymphocyte egress out of the lymph nodes and thymus (10, 11) . S1P interacts with 5 broadly expressed G protein-coupled receptors, S1P [1] [2] [3] [4] [5] . When S1P binds EC S1P 1 , it stabilizes adherens junctions by increasing the translocation of GTPase Rac and VEcadherin to the cell periphery, and resultant homotypic VE-cadherin interactions cause cell spreading and closure of intercellular gaps (12) (13) (14) . Blocking S1P degradation or administration of S1P 1 agonists has been shown to diminish lung inflammation in response to LPS and bleomycin-induced acute lung injury (15, 16) .
We asked whether S1P 1 agonists could decrease inflammation in an animal model of IC-mediated vascular injury, the reverse Arthus reaction (RAR). In this model, ICs activate neutrophils via Fc receptors to release reactive oxygen species, proteolytic enzymes, cytokines, and chemokines. Complement receptors are required in some animal models, depending on the strain and organ in which the RAR is induced (17, 18) . Although vascular injury is a critical pathophysiologic component of the RAR, pharmacologic targeting of the EC barrier has not been studied. In this study, we show that S1P 1 agonists, including a novel engineered S1P chaperone, ApoM-Fc (19) , prevent barrier dysfunction in response to activated neutrophil-induced injury in vitro and diminish neutrophil transmigration and RBC extravasation in vivo. These data support a novel approach to limiting inflammation by enhancing EC barrier integrity, and thus have implications for the treatment of patients with IC-mediated injury.
MATERIALS AND METHODS
Reagents. Specific S1P 1 agonists, CYM-5442 (Santa Cruz Biotechnology) and SEW-2871, and a specific S1P 1 antagonist, W146 (Cayman Chemical), were dissolved in DMSO. A novel engineered S1P chaperone, ApoM-Fc loaded with S1P (19) , was used in vitro (10 lg/ml) and in vivo (4 mg/kg intraperitoneally [IP] ). Human recombinant C5a (100 ng/ml; R&D Systems) was used to activate polymorphonuclear neutrophils (PMNs). The following antibodies were used for Western blotting and/or immunofluorescence: ApoM (ab91656; Abcam), anti-VE-cadherin (C19; Santa Cruz Biotechnology), and anti-pmyosin light chain 2 (anti-p-MLC-2) (T18/S19; Cell Signaling).
In vitro formation of ICs. Goat anti-ovalbumin IgG (500 lg in 300 ll phosphate buffered saline [PBS]) (MP Biomedicals) was incubated with 50 lg ovalbumin for 60 minutes at 37°C. ICs were kept at 4°C overnight, and then centrifuged for 5 minutes at 10,000g. After washing in cold PBS, the pellet was resuspended in 300 ll PBS. Previous work by other laboratories has shown that goat IgG binds human and mouse Fc receptors (20, 21) .
Human umbilical vein endothelial cell (HUVEC) culture and electrical cell-substrate impedance sensing (ECIS) assays. HUVECs (1.5 9 10 5 ; passages 2-8) were cultured on fibronectin-coated 8-well ECIS plates (8W10E; Applied BioPhysics) in M199 supplemented with HEPES, 10% heatinactivated fetal bovine serum (FBS), 10 mM HEPES, penicillin/streptomycin (50 mg/ml), and EC growth factors (Sigma). Cells were plated 18 hours before use and were serum-starved for 2 hours. In experiments using PMNs, ICs (1:20 dilution) and C5a (100 ng/ml) were added to HUVECs 15 minutes prior to the addition of PMNs. HUVECs treated with unstimulated neutrophils were used as a control to validate each experimental run. An AC current (4 kHz) was applied (ECIS Theta; Applied BioPhysics), and resistance measurements were obtained every 5 minutes.
Neutrophil isolation and activation. Ten milliliters of human blood from healthy donors was collected in EDTA. Neutrophils (PMNs) were isolated using Polymorphoprep (Axis-Shield), washed in Hanks' balanced salt solution (HBSS) without cations, resuspended at 1 9 10 6 /ml, and used within 1 hour of isolation. Protocols for human subjects were approved by the Institutional Review Board at the Hospital for Special Surgery, and written informed consent was obtained from each subject.
Immunofluorescence staining. HUVECs (3 9 10 5 ) were cultured on fibronectin-coated culture slides and used when confluent. HUVECs were serum-starved for 2 hours before the addition of S1P 1 agonists or antagonists or ICs (1:20 dilution) and C5a (100 ng/ml). PMNs (1 9 10 5 ) were added 10 minutes after the addition of ICs and C5a. After a 30-minute incubation at 37°C, supernatants were discarded, and wells were washed in PBS. Cells were fixed in paraformaldehyde (4%) at room temperature and permeabilized with Triton X-100 (0.1%). Cells were blocked with 1% FBS for 1 hour at room temperature. To detect p-MLC-2 and VE-cadherin, samples were incubated with anti-p-MLC-2 (5 lg/ml) and anti-VE-cadherin (5 lg/ml) antibodies overnight. After 3 washes, samples were incubated with fluorescent secondary antibodies (Alexa Fluor 488 and Alexa Fluor 568; Invitrogen) for 1 hour at room temperature. Samples were imaged using an Olympus FluoView FV10i confocal microscope.
Mice. Animal experiments were performed under the guidelines set by the Institutional Animal Care and Use Committee at Weill Cornell Medicine. C57BL/6 mice (ages 8-10 weeks) were obtained from The Jackson Laboratory. EC-specific gene deletion of S1PR1 was performed as follows. S1pr1 f/f mice (22) were crossed with Cdh5-CreERT2 mice (23) to establish Cre-positive S1pr1 f/f (S1P 1 EC-knockout [ECKO]) mice and Cre-negative controls. To induce EC knockdown of S1P 1 , 8-10-week-old Crepositive S1pr1 f/f mice and control Cre-negative S1pr1 f/f mice were treated with tamoxifen (10 mg/ml; 200 ll IP) once daily for 5 days. Deletion of S1P 1 exon 2, containing the entire coding region, was confirmed by polymerase chain reaction (Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40558/ abstract). Mice were evaluated 2-4 weeks after tamoxifen administration. ApoM À/À mice were a gift from L. B. Nielsen and C. Christeoffersen (Rigshospitalet, Copenhagen, Denmark) (24) . The absence of apolipoprotein M was confirmed by Western blotting of mouse plasma ( Supplementary Figure 1) .
Reverse Arthus reaction in mouse skin. Anesthetized mice were shaved and injected with intradermal goat antiovalbumin IgG (60 lg/30 ll) or PBS alone. Immediately thereafter, ovalbumin (400 lg; Sigma) and Evans blue (0.5% in 150 ll PBS) were injected via the tail vein. Some mice received intradermal W146 (10 lg) or vehicle concomitantly with anti-ovalbumin IgG. After 4 hours, mice were killed and the diameter of Evans blue leakage was measured. Six-millimeter punch skin samples were weighed and treated with formamide (500 ll at 60°C overnight) to extract Evans blue, and supernatants were measured at 610 nm. In preliminary experiments, we found that nonspecific goat IgG injected intradermally did not elicit a reaction after intravenous (IV) injection of ovalbumin and Evans blue and that goat anti-ovalbumin IgG injected intradermally did not elicit a reaction after IV injection of Evans blue without ovalbumin.
Reverse Arthus reaction in mouse lungs. Mice were anesthetized, and goat anti-ovalbumin IgG (250 lg) was administered intranasally; immediately thereafter, mice were injected with IV 0.5% Evans blue and ovalbumin (750 lg in 150 ll PBS). CYM-5442 (0.5 mg/kg) or SEW-2874 (10 mg/kg) was administered IP (in 25% Tween/75% water) starting 2 hours prior to RAR and then every 5 hours. In some experiments, W146 (10 lg) or vehicle was administered intranasally concomitantly with anti-ovalbumin IgG. Twenty-four hours after RAR, mice were anesthetized and bronchoalveolar lavage (BAL) was performed. Five hundred microliters of PBS with 1 mM EDTA was administered and collected 3 times. Samples (300 ll) were stained with Wright-Giemsa after cytospin. Cell counts were obtained with an automated hemocytometer, and the number of PMNs was calculated by multiplying the total number of white blood cells (WBCs) by the percentage of PMNs assessed on cytospin.
Western blotting. Plasma samples (1 ll) from ApoM
and wild-type (WT) mice were denatured at 95°C for 5 minutes after the addition of 10% b-mercaptoethanol. Proteins were 
RESULTS
Amplified inflammation and hemorrhage in response to lung RAR in mice deficient in EC-specific S1P 1 . The RAR is a well-established model of acute IC-mediated vascular injury and inflammation characterized by neutrophil activation and vascular leakage (25, 26) . Because IC deposition in microvessels correlates with vascular permeability (27), we posited that decreased EC barrier function and the consequent increase in IC deposition would enhance inflammation. To test this hypothesis, we induced lung RAR in mice with ECs lacking S1P 1 (S1P 1 ECKO mice). At baseline, S1P 1 ECKO mice injected with IV Evans blue alone showed increased pulmonary extravasation of Evans blue compared to control mice, indicative of vascular leakage, as previously reported (28); notably, BAL fluid from S1P 1 ECKO mice injected with Evans blue did not show increased numbers of RBCs or WBCs (data not shown). In contrast, after RAR, S1P 1 ECKO mice demonstrated a marked increase in Evans blue extravasation and lung weight ( Figures 1A and B) , as well as a greater number of WBCs and RBCs in the BAL fluid compared to Crenegative littermate controls ( Figures 1C and D) . WBCs in BAL fluid comprised mostly neutrophils (range 50-80%) and alveolar macrophages in both control and S1P 1 ECKO mice ( Figures 1E and F) . Taken together, these findings demonstrate impaired barrier function and increased inflammation in response to RAR in S1P 1 ECKO mice.
Increased lung and skin RAR in mice treated with W146, a specific S1P 1 antagonist. ApoM, a constituent of high-density lipoprotein (HDL), carries~65% of circulating S1P, while albumin carries 30%. Mice lacking ApoM have a 50% reduction in circulating S1P compared to controls (29) , and ApoM delivery of S1P is more protective of barrier function and more antiinflammatory than albumin delivery (30, 31) . Therefore, we hypothesized that ApoM À/À mice would have an increased inflammatory response to RAR. Surprisingly, ApoM À/À mice and WT mice had similar numbers of PMNs and RBCs in BAL fluid after RAR (Figures 2A and B) and similar Evans blue extravasation in their lungs. We considered the possibility that local levels of S1P were elevated by platelets and/or EC release during RAR and obscured the effects of ApoM deficiency. At higher levels of S1P (~500 nM), albumin and ApoM have been shown to be equally effective at reducing levels of tumor necrosis factorinduced vascular cell adhesion molecule 1 in ECs in vitro (32) .
We hypothesized that partial blockade of S1P 1 with an S1P 1 antagonist would render ApoM À/À mice more vulnerable to IC-mediated injury than WT mice, in spite of high local levels of albumin S1P. In preliminary studies, systemic administration of IV W146 (10 mg/kg or a total of 250 lg) induced significant pulmonary leakage, as has been described previously (33) (Supplementary  Figure 2C, Figure 2A) . We reasoned that administration of lower doses of intranasal W146 (10 lg) would not induce vascular leakage at baseline but would limit S1P 1 availability and reveal the protective effect of ApoM-mediated delivery of S1P during RAR. Indeed, low-dose W146 administered intranasally to ApoM À/À mice concomitantly with anti-ovalbumin IgG markedly increased extravasation of RBCs and PMNs from blood vessels into the alveolar space (Figures 2A and B) , while treatment of WT mice with W146 at the same dose did not alter RAR. These data demonstrate that decreased signaling of S1P 1 (induced by partial blockade of S1P 1 with W146) increases vulnerability to EC barrier dysfunction during IC-mediated inflammation which can be overcome by delivery of S1P by ApoM.
Because IC-mediated injury in skin is common in patients with SLE, we sought to confirm that modulation of S1P 1 signaling also affects skin RAR. Similar to lung RAR, there was no evidence that ApoM deficiency increased skin RAR in mice, and intradermal injection of low doses of W146 alone did not increase Evans blue leakage in WT mice (Supplementary Figure 3 , available on the Arthritis & Rheumatology web site at http://online library.wiley.com/doi/10.1002/art.40558/abstract). However, in contrast to our findings with regard to lung RAR in WT mice, low-dose W146 (10 lg) increased the severity of skin RAR in WT mice when administered concomitantly with anti-ovalbumin IgG, compared to control reaction sites of anti-ovalbumin alone (Figures 2C-E) . The finding that low-dose W146 augmented skin RAR, but not lung RAR, in WT mice may be explained by a lower density of S1P 1 in the skin compared to lungs (34) . These data show that low doses of locally administered W146 do not induce skin or lung leakage at baseline but augment vascular leakage in IC-mediated injury in the skin of WT mice and in the lungs of ApoM À/ À mice. These findings further support the concept that blockade of S1P 1 receptors increases inflammation in response to IC deposition.
BURG ET AL
The S1P 1 agonist CYM-5442 increases barrier function and mitigates vascular injury induced by activated PMN injury in vitro and in vivo. Given that blockade of S1P 1 signaling increases IC-driven injury, we hypothesized that augmentation of EC barrier function would limit inflammation in response to ICs. We first tested the capacity of CYM-5442, a specific S1P 1 agonist, to increase EC barrier function in vitro with ECIS. CYM-5442 induced a rapid increase in EC resistance at doses of 50-200 nM that returned to baseline after 1. Figure 3A) . C5a or ICs alone did not induce a decrease in HUVEC resistance in ECIS after 1-2 hours (data not shown), but PMNs activated by both C5a and ICs caused a marked decrease in resistance within 30 minutes that was sustained for 8 hours (Figure 3A) . CYM-5442 (200 nM) reversed the PMN-induced drop in resistance ( Figure 3A) , supporting the possibility For the lung RAR, mice were treated with intranasal anti-ovalbumin IgG followed by intravenous (IV) ovalbumin and 0.5% Evans blue. Mice received W146 (10 lg) or vehicle (veh) intranasally concomitantly with anti-ovalbumin IgG. After 24 hours, mice were subjected to bronchoalveolar lavage (BAL). For the skin RAR, mice were injected intradermally with goat anti-ovalbumin IgG and W146 (10 lg) or vehicle (DMSO), followed by IV treatment with ovalbumin and Evans blue, and killed after 4 hours. A and B, Numbers of polymorphonuclear neutrophils (PMNs) (A) and red blood cells (RBCs) (B) in BAL fluid from vehicle-treated and W146-treated WT and ApoM À/À mice after lung RAR. Symbols represent individual mice (n = 6 per group); bars show the mean AE SEM. * = P = 0.04 in A; * = P = 0.005 in B. C, A representative mouse skin sample obtained after RAR, showing Evans blue leakage at the injection sites. D, Area of Evans blue leakage at the injection site in vehicle-treated and W146-treated WT mice after RAR, assessed by measuring the diameter of the major and minor axis. Symbols represent individual mice (n = 6 per group); bars show the mean AE SEM. * = P = 0.006. E, Weight of 6-mm skin punch biopsy specimens obtained from vehicle-treated and W146-treated WT mice after RAR. Symbols represent punch biopsy samples from 6 mice (n = 11-12 samples); bars show the mean AE SEM. * = P = 0.02.
S1P 1 AGONISTS PROTECT AGAINST IC-MEDIATED VASCULAR INJURY
that CYM-5442 diminishes inflammatory injury in the RAR by protecting EC barrier function.
Because CYM-5442 is an S1P 1 agonist that can act as a functional antagonist, inducing internalization and degradation of S1P 1 in a dose-dependent manner, we first determined the dose of CYM-5442 that induced Evans blue leakage. At 10 mg/kg, a dose that has been shown to induce maximal lymphopenia and yield plasma concentrations of~1 lM (35), there was significant Evans blue leakage (Supplementary Figure 2C) . Because our ECIS experiments showed that CYM-5442 was protective of the EC barrier at concentrations of 50-200 nM, we hypothesized that administration of 0.5 mg/kg CYM-5442 to mice would yield a plasma concentration such that it would function as an S1P 1 agonist (50-200 nM) and increase EC barrier function.
In WT mice treated with CYM-5442 (0.5 mg/ kg), the lung RAR was blunted. BAL fluid contained fewer PMNs and RBCs (Figures 3B and C) , but Evans blue extravasation and lung weight were not decreased. Treatment with a much weaker S1P 1 biopsy weight, respectively ( Figures 3E and F) . The finding that CYM-5442 was effective at blocking Evans blue extravasation in the skin, but not the lung, during RAR is consistent with our observation that W146 exacerbated skin, but not lung, RAR in WT mice.
ApoM-Fc, a novel S1P chaperone, protects ECs from loss of barrier integrity induced by activated PMNs and attenuates lung RAR. A novel biologic chaperone of S1P, ApoM-Fc, was recently shown to increase circulating S1P levels by~60% and to attenuate myocardial injury after ischemia-reperfusion injury and reduce brain injury in a mouse model of stroke (19) . In addition, ApoM-Fc increased barrier function to a greater extent than albumin-S1P and did not induce lymphopenia, suggesting specificity to activation of EC S1P receptors, particularly S1P 1 (19) . We examined the ability of ApoM-Fc to attenuate IC-mediated injury initiated by activated PMNs in vitro and in vivo. ApoM-Fc rescued EC barrier function in HUVECs exposed to IC and C5a-activated PMNs in a sustained manner ( Figure 4A ). In comparison, albumin-S1P (200 nM) increased resistance, but the effect was transient ( Figure 4A ).
To determine whether ApoM-Fc is an effective means to deliver S1P to ECs and mitigate IC-mediated injury in vivo, we treated WT mice with ApoM-Fc and initiated lung RAR. ApoM-Fc attenuated the inflammatory response in lung RAR, as indicated by a decrease in the numbers of PMNs and RBCs in BAL fluid ( Figures 4B  and C) , but like CYM-5442 and SEW-2871, there was no effect on Evans blue leakage or lung weight (Figures 4D  and E) . S1P 1 agonists CYM-5442 and ApoM-Fc limit EC phosphorylation of MLC and VE-cadherin junction disassembly in response to IC and C5a-activated neutrophils. Activated neutrophils have been shown to induce the Rho GTPase pathway in EC which contributes to barrier breach, vascular leakage (36) , and neutrophil migration (37) . Phosphorylation of MLC of myosin II induces RhoA-mediated assembly of stress fibers and focal adhesions, mediating cell contraction. We hypothesized that S1P protects ECs from injury induced by activated neutrophils and prevents loss of barrier integrity by inhibiting the Rho pathway. To test this experimentally, we compared p-MLC staining in HUVECs exposed to PMNs activated with ICs and C5a to that of HUVECs exposed to unstimulated PMNs (control HUVECs) ( Figure 5 ). Treatment with activated PMNs markedly increased HUVEC p-MLC staining, which appeared to localize to stress fibers ( Figure 5 ). The p-MLC staining was attenuated in HUVECs preincubated with ApoM-Fc and then treated with IC and C5a-activated PMNs ( Figure 5 ).
Because Rho pathway-mediated endothelial hyperpermeability is associated with disruption of VEcadherin at adherens junctions (38), we determined whether ApoM-Fc protected VE-cadherin localization in HUVECs treated with PMNs activated with both ICs and C5a. HUVECs treated with activated PMNs showed marked loss of VE-cadherin staining, whereas HUVECs pretreated with ApoM-Fc showed mostly intact staining ( Figure 5) . Similarly, HUVECs pretreated with CYM-5442 were protected against PMN-induced injury, demonstrating preserved VE-cadherin and attenuated p-MLC (Supplementary Figure 5 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.40558/abstract). Taken together, these data suggest that S1P agonists protect ECs against neutrophil-mediated induction of the Rho pathway.
DISCUSSION
Herein we present genetic and pharmacologic evidence that S1P 1 signaling in ECs modulates vascular responses to IC deposition. Deletion of S1P 1 in ECs augmented vascular leakage and inflammation induced by the RAR, suggesting a protective role of S1P 1 . This was supported by evidence that W146, a specific S1P 1 antagonist, decreased EC barrier function in vitro and increased skin and lung RAR. Finally, 2 S1P 1 agonists, CYM-5442 and SEW-2871, and a novel biologic chaperone of S1P, ApoM-Fc, protected EC barrier integrity against injury induced by IC-activated PMNs in vitro and in vivo. Taken together, our results demonstrate that S1P 1 signaling enhances the EC barrier, limits leukocyte escape from capillaries, and provides protection against inflammatory injury. In addition, we show that S1P 1 agonists prevent VE-cadherin disruption and phosphorylation of MLC, a potential mechanism by which they maintain vascular barrier integrity despite pathogenic mediators released by activated PMNs.
While the S1P 1 agonists were effective in decreasing inflammation, they did not significantly reduce Evans blue extravasation or plasma escape from the microvasculature. Enhanced S1P 1 signaling during IC-mediated inflammation may not be sufficient to block transudation of small molecules, such as albumin, but it appears sufficient to prevent transmigration of PMNs and leakage of RBCs at sites of barrier breaks. It is also possible that S1P 1 agonists decrease the migration of inflammatory cells at sites of inflammation, at least in part, by influencing the phosphorylation status of VE-cadherin; phosphorylation of T685 on the cytoplasmic domain of VE-cadherin supports permeability, while dephosphorylation of T731 supports leukocyte transmigration (39) . In contrast to our findings in the lung, CYM-5442 decreased Evans blue extravasation and skin weight in the skin RAR in mice. This may be due to the lower density of S1P 1 receptors in the skin compared to the lungs. Alternatively, there may be differential expression of S1P family receptors or other receptors on ECs that determine vascular barrier function in different vascular beds. The ability of low-dose W146 to augment the skin, but not lung, RAR in WT mice also supports the notion of differences in S1P 1 density and/or other receptors influencing permeability in the skin and lung.
Increasing barrier function has been shown to limit inflammation in models of ischemia-reperfusion injury and several other models of acute injury (40, 41) . Although the RAR is also a model of acute inflammation, increasing barrier function to limit the number of activated neutrophils transmigrating into tissues may have long-term consequences on organ function. PMN influx has been identified as a key mediator of renal damage in nephrotoxic serum transfer, a model of IC-initiated glomerulonephritis (42) . Reducing exposure to neutrophil-derived chemokines, cytokines, reactive oxidants, and proteolytic enzymes limits acute damage and allows resolution of damage. The critical role of microvascular integrity in limiting joint damage and PMN infiltration is also supported in the K/BxN serum-transfer model of RA (3). Indeed, blood vessels in joints appear to be more susceptible to IC-mediated injury than vasculature in other tissues (43) .
Despite the body of evidence demonstrating the key role of microvasculature in regulation of tissue injury induced by inflammation, pharmacologic targeting of ECs to increase barrier function in RA and SLE has not been pursued. Drug discovery and development for SLE and RA targeting the S1P/S1P 1 axis has focused solely on restricting the egress of pathogenic lymphocytes from lymph nodes and induction of circulating lymphopenia (44) . Because of their ability to induce lymphopenia, S1P 1 antagonists have been studied in mouse models of inflammatory arthritis (45) , and while blocking autoreactive T cells from entering target tissues is beneficial for reducing inflammation and organ damage, the effects on ECs may be deleterious. Indeed, prolonged treatment of mice with adjuvant-induced arthritis with the S1P 1 antagonist NIBR-0213 decreased joint inflammation but resulted in pulmonary edema, perivascular fibrosis, and functional lung impairment (46) . Because patients with SLE and RA frequently have lung involvement, they may be more vulnerable to pulmonary vascular leakage and inflammation.
The clinical efficacy of FTY-720, a nonspecific S1P receptor agonist/functional antagonist that also induces lymphopenia, for the treatment of multiple sclerosis has encouraged development of several S1P 1 -specific agonists/antagonists for the treatment of other autoimmune diseases (44) . In animal models of lupus nephritis, both FTY-720 and the specific S1P 1 receptor agonist KRP-203 induced lymphopenia, reduced renal injury, and increased survival (47, 48) . A problem with this approach is that depending on the dose and frequency of its delivery, FTY-720 has been shown to induce and/or exacerbate vascular leakage in the lung and brain (49, 50) ; the mechanism by which FTY-720 can impair vascular integrity involves S1P 1 phosphorylation, internalization, and proteasomal degradation (33) . CYM-5442, while efficacious at low doses in our study, had a limited therapeutic window because it, too, increased vascular leakage at high doses, consistent with its ability to induce S1P 1 internalization and proteasomal degradation (35) . ApoM-Fc has the potential to effectively enhance delivery of S1P without leading to excessive S1P 1 internalization. An additional advantage of ApoM-Fc is that its half-life is 4 days compared to 4-5 hours for CYM-5442 or SEW-2871. Finally, ApoM-Fc does not induce lymphopenia, but formal studies on the effects of ApoM-Fc on leukocyte function are ongoing to determine whether it is immunosuppressive. Novel approaches to target the S1P/S1P 1 axis, particularly in systemic diseases that put patients at risk of pulmonary vascular leakage, are needed to augment barrier function without causing degradation of S1P 1 . Such interventions could be used as adjuncts to immunosuppressive therapy, allowing simultaneous targeting to decrease production of autoantibodies and to attenuate tissue responses to IC deposition. Our data support further studies in models of chronic inflammatory injury to determine whether S1P 1 -augmented EC barrier function mitigates end-organ damage.
